Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

Audentes Therapeutics, Inc. (BOLD) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/15/2020 4 Soloway Thomas P (Executive Vice President, CFO) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Unknown transaction of 183,384 shares @ $60, valued at $11M
Disposed/sold 3,829 options to buy @ $2.7649, valued at $10.6k
Disposed/sold 6,263 options to buy @ $9.4988, valued at $59.5k
Disposed/sold 73,781 options to buy @ $15.26, valued at $1.1M
Disposed/sold 75,000 options to buy @ $27.39, valued at $2.1M
Disposed/sold 65,000 options to buy @ $24.74, valued at $1.6M
01/15/2020 4 Smith Julie (Director) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Disposed/sold 18,000 options to buy @ $17.85, valued at $321.3k
Disposed/sold 9,000 options to buy @ $0
Disposed/sold 10,000 options to buy @ $38.65, valued at $386.5k
Disposed/sold 16,200 options to buy @ $24.74, valued at $400.8k
01/15/2020 4 Schuetz Thomas J. (Director) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Unknown transaction of 89,695 shares @ $60, valued at $5.4M
Disposed/sold 18,086 options to buy @ $0.7804, valued at $14.1k
Disposed/sold 5,605 options to buy @ $2.1852, valued at $12.2k
Disposed/sold 9,000 options to buy @ $15.03, valued at $135.3k
Disposed/sold 9,000 options to buy @ $0
Disposed/sold 10,000 options to buy @ $38.65, valued at $386.5k
Disposed/sold 16,200 options to buy @ $24.74, valued at $400.8k
01/15/2020 4 Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Unknown transaction of 261,458 shares @ $60, valued at $15.7M
Unknown transaction of 171,814 shares @ $60, valued at $10.3M
Disposed/sold 143,569 options to buy @ $9.4988, valued at $1.4M
Disposed/sold 188,334 options to buy @ $15.26, valued at $2.9M
Disposed/sold 225,000 options to buy @ $27.39, valued at $6.2M
Disposed/sold 177,450 options to buy @ $24.74, valued at $4.4M
01/15/2020 4 Mosbrooker Eric (SVP, Chief Commercial Officer) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Unknown transaction of 26,919 shares @ $60, valued at $1.6M
Disposed/sold 87,750 options to buy @ $22.01, valued at $1.9M
01/15/2020 4 Morrison Scott W (Director) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Disposed/sold 33,635 options to buy @ $9.4988, valued at $319.5k
Disposed/sold 9,000 options to buy @ $15.03, valued at $135.3k
Disposed/sold 9,000 options to buy @ $0
Disposed/sold 10,000 options to buy @ $38.65, valued at $386.5k
Disposed/sold 16,200 options to buy @ $24.74, valued at $400.8k
01/15/2020 4 Meltz Mark A (SVP, General Counsel) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Unknown transaction of 32,705 shares @ $60, valued at $2M
Disposed/sold 104,000 options to buy @ $37.26, valued at $3.9M
01/15/2020 4 LANGE LOUIS G (Director) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Unknown transaction of 265,799 shares @ $60, valued at $15.9M
Unknown transaction of 13,678 shares @ $60, valued at $820.7k
Unknown transaction of 32,343 shares @ $60, valued at $1.9M
Unknown transaction of 3,555 shares @ $60, valued at $213.3k
Disposed/sold 18,000 options to buy @ $15.03, valued at $270.5k
Disposed/sold 9,000 options to buy @ $0
Disposed/sold 10,000 options to buy @ $38.65, valued at $386.5k
Disposed/sold 16,200 options to buy @ $24.74, valued at $400.8k
01/15/2020 4 Jarrett Jennifer (Director) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Disposed/sold 18,000 options to buy @ $14.7, valued at $264.6k
Disposed/sold 9,000 options to buy @ $0
Disposed/sold 10,000 options to buy @ $38.65, valued at $386.5k
Disposed/sold 16,200 options to buy @ $24.74, valued at $400.8k
01/15/2020 4 Holles Natalie C. (President and COO) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Unknown transaction of 104,439 shares @ $60, valued at $6.3M
Disposed/sold 110,703 options to buy @ $2.7649, valued at $306.1k
Disposed/sold 548 options to buy @ $9.4988, valued at $5.2k
Disposed/sold 40,883 options to buy @ $15.26, valued at $623.9k
Disposed/sold 93,109 options to buy @ $27.39, valued at $2.6M
Disposed/sold 25,000 options to buy @ $36.39, valued at $909.8k
Disposed/sold 50,105 options to buy @ $24.74, valued at $1.2M
01/15/2020 4 Goldberg Mark Alan (Director) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Unknown transaction of 1,500 shares @ $60, valued at $90k
Disposed/sold 18,000 options to buy @ $33.91, valued at $610.4k
Disposed/sold 4,500 options to buy @ $38, valued at $171k
Disposed/sold 10,000 options to buy @ $38.65, valued at $386.5k
Disposed/sold 16,200 options to buy @ $24.74, valued at $400.8k
01/15/2020 4 Conner Edward R. (SVP, Chief Medical Officer) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Unknown transaction of 24,584 shares @ $60, valued at $1.5M
Disposed/sold 90,000 options to buy @ $36.08, valued at $3.2M
01/10/2020 4 Soloway Thomas P (Executive Vice President, CFO) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Exercised 144,669 options to buy @ $2.7649, valued at $400k
Exercised 6,219 options to buy @ $15.26, valued at $94.9k
01/10/2020 4 Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Gifted 12,500 shares @ $0
Exercised 64,751 options to buy @ $0.78, valued at $50.5k
Exercised 74,297 options to buy @ $2.19, valued at $162.7k
Exercised 11,824 options to buy @ $9.5, valued at $112.3k
Exercised 11,666 options to buy @ $15.26, valued at $178k
12/27/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/16/2019 4 Soloway Thomas P (Executive Vice President, CFO) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Paid exercise price by delivering 8,681 shares @ $59.37, valued at $515.4k
Paid exercise price by delivering 21,458 shares @ $59.37, valued at $1.3M
Exercised 41,321 options to buy @ $2.7649, valued at $114.2k
12/16/2019 4 Mosbrooker Eric (SVP, Chief Commercial Officer) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Paid exercise price by delivering 4,881 shares @ $59.37, valued at $289.8k
12/16/2019 4 Meltz Mark A (SVP, General Counsel) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Paid exercise price by delivering 4,628 shares @ $59.37, valued at $274.8k
12/16/2019 4 Holles Natalie C. (President and COO) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Paid exercise price by delivering 8,681 shares @ $59.37, valued at $515.4k
Paid exercise price by delivering 88,928 shares @ $59.37, valued at $5.3M
Exercised 45,726 options to buy @ $2.7649, valued at $126.4k
Exercised 5,715 options to buy @ $9.4988, valued at $54.3k
Exercised 74,117 options to buy @ $15.26, valued at $1.1M
Exercised 6,891 options to buy @ $27.39, valued at $188.7k
Exercised 14,895 options to buy @ $24.74, valued at $368.5k
12/16/2019 4 Conner Edward R. (SVP, Chief Medical Officer) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Paid exercise price by delivering 5,416 shares @ $59.37, valued at $321.5k
12/09/2019 4 Soloway Thomas P (Executive Vice President, CFO) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Paid exercise price by delivering 505 shares @ $59.21, valued at $29.9k
12/09/2019 4 Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Paid exercise price by delivering 1,974 shares @ $59.21, valued at $116.9k
12/09/2019 4 Holles Natalie C. (President and COO) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Paid exercise price by delivering 505 shares @ $59.21, valued at $29.9k
11/12/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/25/2019 4 LANGE LOUIS G (Director) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Sold 9,755 shares @ $32.149, valued at $313.6k
Sold 245 shares @ $32.6628, valued at $8k
Sold 1,000 shares @ $32.182, valued at $32.2k
09/09/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/09/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/09/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/14/2019 4 Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Sold 19,000 shares @ $34.0163, valued at $646.3k
Sold 1,000 shares @ $34.525, valued at $34.5k
Exercised 20,000 options to buy @ $9.5, valued at $190k
07/17/2019 4 Conner Edward R. (SVP, Chief Medical Officer) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Granted 30,000 shares @ $0
Granted 90,000 options to buy @ $36.08, valued at $3.2M
06/26/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/07/2019 4 PRASAD SUYASH (Senior VP & Chief Med Officer) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Paid exercise price by delivering 757 shares @ $37.31, valued at $28.2k
06/07/2019 4 Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Paid exercise price by delivering 3,332 shares @ $37.31, valued at $124.3k
06/07/2019 4 Holles Natalie C. (President and COO) has filed a Form 4 on Audentes Therapeutics, Inc.
Txns: Paid exercise price by delivering 1,009 shares @ $37.31, valued at $37.6k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy